TBio-4101 (TIL)

Tumor-infiltrating lymphocytes · Turnstone Biologics, Corp.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TBio-4101 (TIL), covering 2025-03-10 to 2025-03-10. Get the full timeline:

Most recent: Clinical Trial Update: A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors [Phase 1]